Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Novartis |
---|---|
Information provided by: | Novartis |
ClinicalTrials.gov Identifier: | NCT00171353 |
One hundred twenty patients with arterial hypertension and albuminuria (some amount of albumin in urine) are given valsartan 80 mg and then160 mg to normalize blood pressure. Hydrochlorothiazide (diuretic) 12.5-25 mg added if necessary.
Condition | Intervention | Phase |
---|---|---|
Hypertension |
Drug: valsartan |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Study to Describe Vascular and Renal Effects and Safety of Valsartan 80 and 160 mg in Arterial Hypertension Patients |
Estimated Enrollment: | 140 |
Study Start Date: | July 2004 |
Estimated Primary Completion Date: | September 2005 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 30 Years to 65 Years |
Genders Eligible for Study: | Both |
Inclusion Criteria:
Exclusion Criteria:
Other protocol-defined exclusion criteria may apply
Study ID Numbers: | CVAL489ARU01 |
Study First Received: | September 12, 2005 |
Last Updated: | September 19, 2008 |
ClinicalTrials.gov Identifier: | NCT00171353 History of Changes |
Health Authority: | Russia: Pharmacological Committee, Ministry of Health |
arterial hypertension albuminuria valsartan |
Albuminuria Vascular Diseases Cardiovascular Agents |
Antihypertensive Agents Valsartan Hypertension |
Therapeutic Uses Vascular Diseases Cardiovascular Diseases Cardiovascular Agents |
Antihypertensive Agents Pharmacologic Actions Valsartan Hypertension |